On April 20, Shanghai Kehua Bio-Engineering Co.Ltd(002022) disclosed the performance forecast for 2021. In 2021, the company achieved an operating revenue of 4.469 billion yuan, an increase of 7.55% year-on-year; The net profit attributable to shareholders of listed companies was 721 million yuan, an increase of 6.76% year-on-year; Non net profit attributable to shareholders of listed companies was 705 million yuan, with a year-on-year increase of 6.92%. The basic earnings per share is 1.4 yuan.
The announcement also said that the management of the holding subsidiary “Tianlong company” violated the provisions of the listed company on the management rules and regulations of the holding subsidiary, violated the provisions of the articles of association of Tianlong company, refused to implement the resolutions made by the board of directors of Tianlong company, refused to cooperate with Lixin accountant to carry out the audit work in 2021, and refused to provide important information such as the financial books of Tianlong company in 2021, As a result, the 2021 financial report may be issued with “unable to express an opinion” audit report by Lixin certified public accountants. According to the Listing Rules of Shenzhen Stock Exchange, the company’s shares may be subject to delisting risk warning. Please pay attention to the investment risk.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) disclosed the announcement of major events on December 28, 2021: Li Ming, general manager of Tianlong company, the holding subsidiary of the listed company, sent a letter to the chairman, President and chief financial officer of the company via email on December 25, 2021, saying that he was unable to cooperate with the pre-trial meeting statement and subsequent audit of the listed company at present.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) believes that the company legally holds 62% of the equity of Tianlong company and is the controlling shareholder of Tianlong company. Tianlong company accepts the audit of the audit institution entrusted by the company, which is not only its responsibility as a holding subsidiary of the listed company, but also its obligation stipulated in the articles of association. The management and relevant responsible persons of Tianlong company shall not obstruct the normal audit work of listed companies on the basis of disputes between shareholders of Tianlong company.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) said that the company always has the greatest patience and hopes that both parties can properly resolve the audit differences to ensure that the audit of Tianlong’s 2021 annual report and the audit and information disclosure of Tianlong’s 2021 annual report can be completed on time.
